[Skip to Content]
[Skip to Content Landing]
Article
July 1977

Atropine Inhibition of Echothiophate Cataractogenesis in Monkeys

Author Affiliations

From the Department of Medical Pharmacology, University of Uppsala, Uppsala, Sweden (Drs Kaufman and Bárány), the Department of Ophthalmology, University of Wisconsin Medical School, Madison (Dr Kaufman), and the Department of Ophthalmology, Sabbatsberg Hospital, Stockholm, Sweden (Dr Axelsson).

Arch Ophthalmol. 1977;95(7):1262-1268. doi:10.1001/archopht.1977.04450070160017
Abstract

• One cynomolgus and three vervet monkeys were treated topically twice daily in one eye with 63 μg of echothiophate iodide and 750 μg of atropine sulfate. The opposite eyes were treated with echothiophate alone. The eyes treated with echothiophate alone all developed posterior and/or anterior subcapsular cataracts within 26 to 66 days. The echothiophate plus atropine-treated cynomolgus eye developed a cataract of much delayed onset and lesser severity compared to its echothiophate-only-treated fellow. None of the echothiophate plus atropine-treated vervet eyes developed cataracts during the 121 (two eyes) or 231 (one eye) days of treatment. After 121 days of echothiophate plus atropine treatment, two vervet eyes were switched to echothiophate alone. Both eyes developed unequivocal posterior and anterior subcapsular lens opacities, one within 51 and one within 71 days after the switch. We conclude that atropine inhibits echothiophate cataractogenesis in vervet and cynomolgus monkeys.

(Arch Ophthalmol 95:1262-1268, 1977)

×